Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...

Five years ago, high schools and universities across the country went on spring break a few weeks early. Then, spring break ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Here the authors characterise the cellular and molecular progression of lung alveolar damage in severe COVID-19 patients using integrated histopathology and cell atlassing, pinpointing a role for ...

SARS-CoV-2 has been evolving the ability to evade the immune system about twice as fast as the fastest-evolving flu virus. It ...

Research identifies how viral respiratory infection damages macrophages and suggests treatment with a pre-existing FDA approved drug.

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...